Company News
Biogen Shares Rise 2% on Positive Alzheimer’s Trial
Biogen shares rose about 2% after presenting Phase 2 CELIA data on investigational Alzheimer’s drug diranersen.
The 60 mg dose showed 42% slowing on ADAS‑Cog13, 50% on MMSE, and 26% on CDR‑SB at 18 mo
